denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: GlaxoSmithKline, Janssen, Oncopeptides
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Therapies, Combinations, Clinically relevant
Hematology Disease Topics & Pathways:
Therapies, Combinations, Clinically relevant
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Sagar Lonial, MD, Winship Cancer Institute of Emory University
Disclosures:
Lonial: Takeda: Consultancy, Other: Personal fees, Research Funding; Novartis: Consultancy, Honoraria, Other: Personal fees; Janssen: Consultancy, Honoraria, Other: Personal fees, Research Funding; Genentech: Consultancy; Karyopharm: Consultancy; Sanofi: Consultancy; Amgen: Consultancy, Honoraria, Other: Personal fees; Millennium: Consultancy, Honoraria; Onyx: Honoraria; Merck: Consultancy, Honoraria, Other: Personal fees; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; JUNO Therapeutics: Consultancy; Abbvie: Consultancy; BMS: Consultancy, Honoraria, Other: Personal fees, Research Funding; GSK: Consultancy, Honoraria, Other: Personal fees.
Speakers:
Kenneth Anderson, MD, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute
,
Pieter Sonneveld, MD, PhD, Department of Hematology, Erasmus MC Cancer Institute
and
Peter Voorhees, MD, Levine Cancer Institute, Atrium Health
Disclosures:
Anderson: Celgene: Membership on an entity's Board of Directors or advisory committees; Millenium-Takeda: Membership on an entity's Board of Directors or advisory committees; Oncopep and C4 Therapeutics.: Other: Scientific Founder of Oncopep and C4 Therapeutics.; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Sonneveld: Sanofi: Consultancy; Celgene: Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding; Skyline Dx: Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding. Voorhees: GSK: Honoraria, Other: Other relationship; Adaptive Biotechnologies: Honoraria, Other: Other relationship; Janssen: Honoraria, Other: Other relationship; TeneBio: Honoraria, Other: Other relationship; Oncopeptides: Honoraria, Other: Other relationship; Novartis: Honoraria, Other: Other relationship; BMS/Celgene: Honoraria, Other: Other relationship.
Clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This live streamed educational symposium will involve 4 world renowned experts actively engaged in the management of patients with Multiple Myeloma. Join us and listen to the experts debate the most pressing topics in MM. Polling questions, short didactic sessions, and Q&A opportunities will also be provided. Don’t forget to visit BioAscend.com to view an accredited videotaped discussion highlighting the most clinically relevant data presented which will be available 4 to 6 weeks after the symposium.
See more of: Satellite Symposia